Diabetes Research and Clinical Practice
Volume 77, Issue 1 , Pages 84-91 , July 2007

Improving metabolic control in sub-optimally controlled subjects with Type 1 diabetes: Comparison of two treatment algorithms using insulin glargine

  • Ramon Gomis

      Affiliations

    • Endocrinology and Diabetes Unit, Hospital Clínic Universitari, IDIBAPS, Barcelona University, Barcelona, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 932 279 846; fax: +34 934 516 638.
    • ,
  • Fred Storms

      Affiliations

    • Mesos Diabetes Centrum, Utrecht, The Netherlands
    • ,
  • Ignacio Conget

      Affiliations

    • Endocrinology and Diabetes Unit, Hospital Clínic Universitari, IDIBAPS, Barcelona University, Barcelona, Spain
    • ,
  • Patrick Sinnassamy

      Affiliations

    • sanofi-aventis InterContinental, Paris, France
    • ,
  • Melanie Davies

      Affiliations

    • Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
    • ,
  • on behalf of the AT.LANTUS Study Group

Received 19 May 2006 ,Accepted 2 October 2006.

References 

  1. Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diab. Med. 2004;21:1213–1220
  2. The American Association of Clinical Endocrinologists . Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management—2000 update. Endocr. Pract. 2000;6:43–84
  3. Cryer P. Hypoglycemia is the limiting factor in the management of diabetes. Diab. Metab. Res. Rev. 1999;15:42–46
  4. DeWitt DE, Hirsch IB. Outpatient insulin therapy in Type 1 and Type 2 diabetes mellitus: scientific review. JAMA. 2003;289:2254–2264
  5. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with Type 1 diabetes. Diab. Metab. Res. Rev. 2005;21:545–553
  6. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with Type 1 diabetes. Diab. Care. 2000;23:1666–1671
  7. Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diab. Med. 2006;23:285–292
  8. Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, et al. Intensive replacement of basal insulin in patients with Type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diab. Care. 2003;26:1490–1496
  9. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Int. Med. J. 2005;35:536–542
  10. Aventis, LANTUS® prescribing information, 2003.
  11. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46:271–286
  12. The Diabetes Control and Complications Trial Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am. J. Med. 1991;90:450–459
  13. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diab. Care. 2005;28:1282–1288
  14. Hillman N, Herranz L, Grande C, Villaroel A, Pallardo LF. Is HbA(1c) influenced more strongly by preprandial or postprandial glycemia in Type 1 diabetes?. Diab. Care. 2002;25:1100–1101
  15. Hillman N, Herranz L, Grande C, Vaquero PM, Pallardo LF. What is the relative contribution of blood glucose levels at different time points of the day to HbA1c in Type 1 diabetes?. Diab. Med. 2004;21:468–470
  16. Bailar JC. The powerful placebo and the Wizard of Oz. N. Engl. J. Med. 2001;344:1630–1632
  17. Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with Type 1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diab. Care. 2000;23:1137–1142
  18. Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycaemia: the size of the problem. Diab. Metab. Res. Rev. 2004;20(Suppl. 2):S32–S42
  19. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977–986

☆ Data from this manuscript were presented at the European Association for the Study of Diabetes Congress, Munich, Germany, 5–9 September 2004: I. Conget, et al. Diabetologia 47(Suppl. 2) (2004) Abstract 83; R. Gomis, et al. Diabetologia 47(Suppl. 2) (2004) Abstract 911; I. Raz, et al. Diabetologia 47(Suppl. 2) (2004) Abstract 848; F. Storms, et al. Diabetologia 47(Suppl. 2) (2004) Abstract 910.

PII: S0168-8227(06)00458-X

doi: 10.1016/j.diabres.2006.10.002

Diabetes Research and Clinical Practice
Volume 77, Issue 1 , Pages 84-91 , July 2007

Article Tools